Amanta Healthcare Q1 FY27 Results

Amanta Healthcare's Q1 FY27 revenue grew 6.15% to ₹69 crore, up from ₹65 crore in Q1 FY26. EBITDA remained stable at ₹15 crore. Profit After Tax (PAT) declined by 25% to ₹3 crore, compared to ₹4 crore in the previous year.

Reader Takeaway: Revenue growth is steady, but margin pressure and PAT decline are immediate concerns. Solar plant savings are a future positive.

What just happened

Amanta Healthcare announced its financial results for the first quarter of FY27. The company reported a 6.15% rise in revenue to ₹69 crore. However, its profit after tax saw a significant drop of 25% to ₹3 crore from ₹4 crore in the year-ago period. EBITDA was flat at ₹15 crore.

Why this matters

The results indicate top-line growth driven by operational expansion, but profitability is being squeezed. The decline in PAT, despite revenue growth, highlights cost pressures. The commissioning of a new solar plant is a key strategic move aimed at mitigating these cost pressures and improving future margins.

The backstory

Amanta Healthcare is focused on expanding its manufacturing capacities for sterile liquid products. The company has been investing in capacity building, aiming for a significant revenue growth rate. The current results reflect a transition phase where new capacities are being ramped up, and cost management is crucial.

What changes now

The commissioning of the 10.8 MW captive solar power plant, costing ₹34.8 crore, is expected to generate annual savings of ₹9 crore. This is projected to provide a structural tailwind for EBITDA margins starting from Q2FY27. Furthermore, the expansion of SteriPort and SVP capacities, slated for commissioning in Q2FY27 and Q4FY27 respectively, aims to support the company's target of over 20% revenue CAGR.

Risks to watch

The primary risk is the continued impact of inflationary cost pressures on margins, as seen in the Q1 FY27 EBITDA margin of 21% (down from 23% YoY). The successful ramp-up of new capacities and the realization of cost savings from the solar plant are critical to improving profitability.

Peer comparison

While specific peer comparisons are not detailed in the filing, the industry typically faces challenges related to input costs, regulatory compliance, and capacity utilization. Amanta's focus on sterile injectables and solar power integration are strategic differentiators.

Context metrics (time-bound)

In Q1 FY27, Amanta Healthcare's revenue increased by 6.15% YoY. EBITDA remained flat at 0% change YoY. PAT decreased by 25% YoY. The EBITDA margin stood at approximately 21% for Q1 FY27, compared to 23% in Q1 FY26.

What to track next

Investors should monitor the EBITDA margins in subsequent quarters to assess the impact of the solar plant. Additionally, tracking the revenue growth from newly commissioned capacities and the company's progress on its deleveraging goals will be important.